{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:06Z","timestamp":1793041206270,"version":"4.5.0"},"reference-count":248,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.intimp.2024.112724","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:37:02Z","timestamp":1722641822000},"page":"112724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7961-369X","authenticated-orcid":false,"given":"Qiongxiao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/jmf.2017.3939","article-title":"The effect of aronia berry on type 1 diabetes in vivo and in vitro","volume":"21","author":"Jeon","year":"2018","journal-title":"J. Med. Food"},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20141384","article-title":"Pancreatic \u03b2-cell identity, glucose sensing and the control of insulin secretion","volume":"466","author":"Rutter","year":"2015","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1099-0895(199803)14:1<31::AID-DMR201>3.0.CO;2-A","article-title":"Putative environmental factors in type 1 diabetes","volume":"14","author":"\u00c5kerblom","year":"1998","journal-title":"Diabetes Metab. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-017-0958-6","article-title":"Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study","volume":"15","author":"Rogers","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2024.112724_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","article-title":"B7\/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes","volume":"12","author":"Salomon","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.112724_b0035","doi-asserted-by":"crossref","unstructured":"L. Chatenoud, et al., Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice, Proc. Natl. Acad. Sci., 1994. 91(1): p. 123-127.","DOI":"10.1073\/pnas.91.1.123"},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2013.05.001","article-title":"Anti-CD3 clinical trials in type 1 diabetes mellitus","volume":"149","author":"Daifotis","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0045","doi-asserted-by":"crossref","first-page":"1219598","DOI":"10.3389\/fimmu.2023.1219598","article-title":"Diabetic complications and prospective immunotherapy","volume":"14","author":"Reynolds","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0050","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/stem.3151","article-title":"Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance","volume":"38","author":"Negi","year":"2020","journal-title":"Stem Cells"},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0060","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0075","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transplant."},{"issue":"14","key":"10.1016\/j.intimp.2024.112724_b0080","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"297","author":"Voltarelli","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2024.112724_b0085","unstructured":"N. Mpofu et al. High therapeutic potential of antigen-specific regulatory T cells for therapy of type 1 diabetes, in: Diabetes, Amer Diabetes Assoc 1701 N Beauregard ST, Alexandria, VA 22311-1717 USA, 2009."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"378","key":"10.1016\/j.intimp.2024.112724_b0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8848","article-title":"A divergent population of autoantigen-responsive CD4+ T cells in infants prior to \u03b2 cell autoimmunity","volume":"9","author":"Heninger","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2006.03244.x","article-title":"Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes","volume":"148","author":"Di Lorenzo","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0105","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4049\/jimmunol.166.2.908","article-title":"Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2. 5 nonobese diabetic mice","volume":"166","author":"Judkowski","year":"2001","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0110","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.4049\/jimmunol.152.4.2042","article-title":"Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice","volume":"152","author":"Nagata","year":"1994","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0115","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.2337\/db11-1784","article-title":"Cytotoxic mechanisms employed by mouse T cells to destroy pancreatic \u03b2-cells","volume":"61","author":"Varanasi","year":"2012","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0120","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.kint.2017.04.018","article-title":"Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy","volume":"92","author":"Galsgaard","year":"2017","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0125","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.mpmed.2010.08.012","article-title":"Neuropathy in diabetes","volume":"38","author":"Tesfaye","year":"2010","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jdiacomp.2014.11.013","article-title":"Glycemic variability and diabetes retinopathy: a missing link","volume":"29","author":"Hsu","year":"2015","journal-title":"J. Diabetes Complications"},{"issue":"17","key":"10.1016\/j.intimp.2024.112724_b0140","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/archinternmed.2008.2","article-title":"Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus","volume":"168","author":"De Boer","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.intimp.2024.112724_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101288","article-title":"The dark side of insulin: A primary autoantigen and instrument of self-destruction in type 1 diabetes","volume":"52","author":"Harrison","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.intimp.2024.112724_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2018.12.003","article-title":"Advances in immunotherapy of type I diabetes","volume":"139","author":"Ni","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2337\/dc06-1233","article-title":"Prediction of clinical outcome in islet allotransplantation","volume":"30","author":"Bertuzzi","year":"2007","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0160","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MOT.0000000000000687","article-title":"Mimicking nature-made beta cells: recent advances towards stem cell-derived islets","volume":"24","author":"Tremmel","year":"2019","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nri1332","article-title":"Clinical islet transplantation: advances and immunological challenges","volume":"4","author":"Ricordi","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fimmu.2018.00392","article-title":"Peptide immunotherapy for type 1 diabetes\u2014clinical advances","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/ITT.S117264","article-title":"Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes","volume":"6","author":"Itoh","year":"2017","journal-title":"ImmunoTargets and Therapy"},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-017-0863-6","article-title":"Cell therapy for type 1 diabetes: current and future strategies","volume":"17","author":"Aghazadeh","year":"2017","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.intimp.2024.112724_b0185","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","article-title":"Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases","volume":"9","author":"Naran","year":"2018","journal-title":"Front. Microbiol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0190","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0195","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2337\/diacare.22.3.478","article-title":"Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study","volume":"22","author":"Parving","year":"1999","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0200","first-page":"379","article-title":"Novel autoantigens in type 1 diabetes","volume":"5","author":"Han","year":"2013","journal-title":"Am. J. Transl. Res."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0205","first-page":"1341","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.intimp.2024.112724_b0210","doi-asserted-by":"crossref","unstructured":"M. So, et al., Proinsulin C-peptide is an autoantigen in people with type 1 diabetes, Proc. Natl. Acad. Sci., 115(42): p. 10732-10737, 2018.","DOI":"10.1073\/pnas.1809208115"},{"key":"10.1016\/j.intimp.2024.112724_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.668680","article-title":"Characterization of human CD4 T cells specific for a C-peptide\/C-peptide hybrid insulin peptide","volume":"12","author":"Wiles","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0220","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3\u03b31 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrendo.2009.275","article-title":"Immune therapy for type 1 diabetes mellitus\u2014what is unique about anti-CD3 antibodies?","volume":"6","author":"Chatenoud","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b0230","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/13543784.2022.2022119","article-title":"Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes","volume":"30","author":"Mignogna","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0235","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","article-title":"Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass","volume":"53","author":"Keymeulen","year":"2010","journal-title":"Diabetologia"},{"issue":"40","key":"10.1016\/j.intimp.2024.112724_b0240","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1021\/acs.biochem.9b00707","article-title":"Anti-CD3 antibody for the prevention of type 1 diabetes: a story of perseverance","volume":"58","author":"Gaglia","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2024.112724_b0245","series-title":"The first immunotherapy for type 1 diabetes","first-page":"E185","author":"Velloso","year":"2023"},{"issue":"583","key":"10.1016\/j.intimp.2024.112724_b0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/cei\/uxad083","article-title":"Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes","volume":"214","author":"Christen","year":"2023","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109613","article-title":"Pro-inflammatory \u03b2 cell small extracellular vesicles induce \u03b2 cell failure through activation of the CXCL10\/CXCR3 axis in diabetes","volume":"36","author":"Javeed","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2024.112724_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2017.00343","article-title":"T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes","volume":"8","author":"Burrack","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0270","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0275","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0167-5699(95)80140-5","article-title":"T-cell activation: integration of signals from the antigen receptor and costimulatory molecules","volume":"16","author":"Robey","year":"1995","journal-title":"Immunol. Today"},{"key":"10.1016\/j.intimp.2024.112724_b0280","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2741\/2829","article-title":"Costimulation blockade: towards clinical application","volume":"13","author":"Weaver","year":"2008","journal-title":"Front Biosci"},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b0285","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41590-020-0744-z","article-title":"Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes","volume":"21","author":"Edner","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0290","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyad029","article-title":"The effect of abatacept on T-cell activation is not long-lived in vivo","volume":"3","author":"da Rosa","year":"2024","journal-title":"Discovery Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0295","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1038\/s41467-022-34477-1","article-title":"Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0300","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40259-023-00594-6","article-title":"Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus","volume":"37","author":"Huang","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2024.112724_b0305","doi-asserted-by":"crossref","unstructured":"L.-F. Lee, et al., Anti\u2013IL-7 receptor-\u03b1 reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function, Proc. Natl. Acad. Sci., 109(31): p. 12674-12679, 2012.","DOI":"10.1073\/pnas.1203795109"},{"key":"10.1016\/j.intimp.2024.112724_b0310","doi-asserted-by":"crossref","unstructured":"T. Boettler, M. von Herrath, IL-7 receptor \u03b1 blockade, an off-switch for autoreactive T cells, Proc. Natl. Acad. Sci., 109(31): p. 12270-12271, 2012.","DOI":"10.1073\/pnas.1209749109"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0315","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.dsx.2018.10.008","article-title":"Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention","volume":"13","author":"Tan","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.intimp.2024.112724_b0320","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s11892-013-0415-7","article-title":"Antigen-based vaccination and prevention of type 1 diabetes","volume":"13","author":"Harrison","year":"2013","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.intimp.2024.112724_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00392","article-title":"Peptide immunotherapy for type 1 diabetes\u2014clinical advances","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0330","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMc1616343","article-title":"Intralymphatic injection of autoantigen in type 1 diabetes","volume":"376","author":"Ludvigsson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0335","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrg3069","article-title":"Understanding type 1 diabetes through genetics: advances and prospects","volume":"12","author":"Polychronakos","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b0340","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1464-5491.2012.03710.x","article-title":"Decreased GAD65-specific Th1\/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum","volume":"29","author":"Axelsson","year":"2012","journal-title":"Diabet. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0345","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2337\/dc13-1719","article-title":"GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial","volume":"37","author":"Krause","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/rmv.1815","article-title":"Enteroviruses, hygiene and type 1 diabetes: toward a preventive vaccine","volume":"25","author":"Drescher","year":"2015","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0355","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41467-020-16327-0","article-title":"An integrated multi-omics approach identifies the landscape of interferon-\u03b1-mediated responses of human pancreatic beta cells","volume":"11","author":"Colli","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0360","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41422-019-0161-8","article-title":"LKB1 expressed in dendritic cells governs the development and expansion of thymus-derived regulatory T cells","volume":"29","author":"Pelgrom","year":"2019","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b0365","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/ejhf.2291","article-title":"Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction","volume":"23","author":"Kresoja","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.intimp.2024.112724_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?","volume":"11","author":"Franzin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0375","doi-asserted-by":"crossref","first-page":"1090842","DOI":"10.3389\/fendo.2022.1090842","article-title":"Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes","volume":"13","author":"Ding","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"6316","key":"10.1016\/j.intimp.2024.112724_b0380","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.intimp.2024.112724_b0385","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0390","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune checkpoint inhibitors and risk of type 1 diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"issue":"416","key":"10.1016\/j.intimp.2024.112724_b0395","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2024.112724_b0400","article-title":"Bioengineered artificial extracellular vesicles presenting PD-L1 and Gal-9 Ameliorate New-onset Type 1 Diabetes","author":"Yang","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2024.112724_b0405","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.dci.2017.03.023","article-title":"Zebrafish FOXP3 is required for the maintenance of immune tolerance","volume":"73","author":"Sugimoto","year":"2017","journal-title":"Dev. Comp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0410","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2012.05.031","article-title":"Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict","volume":"150","author":"Samstein","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0415","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0420","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-3083.2008.02159.x","article-title":"Beginning of the end of (understanding) the immune response","volume":"68","author":"Dembic","year":"2008","journal-title":"Scand. J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0425","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.4049\/jimmunol.167.8.4245","article-title":"Activation of CD25+ CD4+ regulatory T cells by oral antigen administration","volume":"167","author":"Zhang","year":"2001","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0430","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ni1037","article-title":"Regulatory T cells mediate maternal tolerance to the fetus","volume":"5","author":"Aluvihare","year":"2004","journal-title":"Nat. Immunol."},{"issue":"6342","key":"10.1016\/j.intimp.2024.112724_b0435","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.aam7928","article-title":"Inflammation and metabolism in tissue repair and regeneration","volume":"356","author":"Eming","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0440","doi-asserted-by":"crossref","first-page":"e0128094","DOI":"10.1371\/journal.pone.0128094","article-title":"FOXP3+ T cells recruited to sites of sterile skeletal muscle injury regulate the fate of satellite cells and guide effective tissue regeneration","volume":"10","author":"Castiglioni","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0445","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2017.05.002","article-title":"Regulatory T cells in skin facilitate epithelial stem cell differentiation","volume":"169","author":"Ali","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0450","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/CIRCRESAHA.115.303895","article-title":"Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte\/macrophage differentiation","volume":"115","author":"Weirather","year":"2014","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0455","first-page":"723","article-title":"Cell interactions in the induction of tolerance: the role of thymic lymphocytes","volume":"18","author":"Gershon","year":"1970","journal-title":"Immunology"},{"issue":"6175","key":"10.1016\/j.intimp.2024.112724_b0460","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/333742a0","article-title":"Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+ 8+ thymocytes","volume":"333","author":"Kisielow","year":"1988","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.intimp.2024.112724_b0465","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.4049\/jimmunol.169.9.4850","article-title":"Homeostasis of Peripheral CD4+ T Cells: IL-2R\u03b1 and IL-2 Shape a Population of Regulatory Cells That Controls CD4+ T Cell Numbers1","volume":"169","author":"Almeida","year":"2002","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0470","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2R\u03b2-deficient mice: implications for the nonredundant function of IL-2","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0475","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat. Genet."},{"issue":"5609","key":"10.1016\/j.intimp.2024.112724_b0480","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0490","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0495","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2004.07.016","article-title":"Suppression of IL7R\u03b1 transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival","volume":"21","author":"Park","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0500","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-065X.2011.01018.x","article-title":"Regulatory T cells and Foxp3","volume":"241","author":"Rudensky","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112724_b0505","doi-asserted-by":"crossref","unstructured":"L. Chatenoud, Natural and induced T CD4+ CD25+ FOXP3+ regulatory T cells. Suppression and Regulation of Immune Responses: Methods and Protocols, p. 3-13, 2011.","DOI":"10.1007\/978-1-60761-869-0_1"},{"key":"10.1016\/j.intimp.2024.112724_b0510","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3389\/fimmu.2017.01578","article-title":"Tregs: where we are and what comes next?","volume":"8","author":"Zhao","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0515","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110831","article-title":"New expression of PD-L1 on activated CD4+ T cells opens up new opportunities for cell interactions and signaling","volume":"85","author":"Mazerolles","year":"2024","journal-title":"Hum. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0525","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0530","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2015.1037282","article-title":"The therapeutic potential of regulatory T cells for the treatment of autoimmune disease","volume":"19","author":"Bluestone","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0535","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro\u2013expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0540","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.4049\/jimmunol.1003224","article-title":"CD4+ FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game","volume":"187","author":"Long","year":"2011","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0545","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126471","article-title":"Stem cell\u2013derived tissue-associated regulatory T cells suppress the activity of pathogenic cells in autoimmune diabetes","volume":"4","author":"Haque","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0550","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4110\/in.2016.16.5.281","article-title":"Development of auto antigen-specific regulatory T cells for diabetes immunotherapy","volume":"16","author":"Song","year":"2016","journal-title":"Immune Network"},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0555","doi-asserted-by":"crossref","first-page":"e0214379","DOI":"10.1371\/journal.pone.0214379","article-title":"Combining anti-IL-7R\u03b1 antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 Diabetes","volume":"14","author":"Vazquez-Mateo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112724_b0560","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02716","article-title":"Metabolic control of Treg cell stability, plasticity, and tissue-specific heterogeneity","volume":"10","author":"Shi","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0565","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/eji.202049123","article-title":"Mechanisms of exTreg induction","volume":"51","author":"Saxena","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nm.3439","article-title":"Good guys gone bad: exTreg cells promote autoimmune arthritis","volume":"20","author":"Joller","year":"2014","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.112724_b0575","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ni.1774","article-title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","volume":"10","author":"Zhou","year":"2009","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0580","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.it.2011.04.002","article-title":"Regulatory T cells: stability revisited","volume":"32","author":"Bailey-Bucktrout","year":"2011","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0585","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1073\/pnas.0811556106","article-title":"Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity","volume":"106","author":"Komatsu","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0590","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.4049\/jimmunol.178.11.6725","article-title":"Cutting edge: regulatory T cells induce CD4+ CD25\u2212 Foxp3\u2212 T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-\u03b2","volume":"178","author":"Xu","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0595","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.immuni.2008.05.007","article-title":"Molecular antagonism and plasticity of regulatory and inflammatory T cell programs","volume":"29","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.112724_b0600","unstructured":"K. Singh, Regulatory T cells in type 1 diabetes: the role of IL-35 in counteracting the disease, Acta Universitatis Upsaliensis, 2017."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0605","doi-asserted-by":"crossref","first-page":"12633","DOI":"10.1038\/srep12633","article-title":"Interleukin-35 administration counteracts established murine type 1 diabetes\u2013possible involvement of regulatory T cells","volume":"5","author":"Singh","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0610","doi-asserted-by":"crossref","first-page":"e33628","DOI":"10.1371\/journal.pone.0033628","article-title":"IL-35 is a novel responsive anti-inflammatory cytokine\u2014a new system of categorizing anti-inflammatory cytokines","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0615","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jir.2021.0147","article-title":"Interleukin-35: structure, function and its impact on immune-related diseases","volume":"41","author":"Ye","year":"2021","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.intimp.2024.112724_b0620","article-title":"IL-35 regulates the function of immune cells in tumor microenvironment","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-019-0217-z","article-title":"IL-35 alleviates inflammation progression in a rat model of diabetic neuropathic pain via inhibition of JNK signaling","volume":"16","author":"Jiang","year":"2019","journal-title":"J. Inflamm."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0630","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/09273948.2016.1203959","article-title":"Levels of interleukin 27 and interleukin 35 in the serum and vitreous of patients with proliferative diabetic retinopathy","volume":"26","author":"Yan","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0635","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.1080\/21655979.2022.2080367","article-title":"Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathy","volume":"13","author":"Yan","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0640","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/osteology1040020","article-title":"Immunomodulatory actions of mesenchymal stromal cells (MSCs) in osteoarthritis of the knee","volume":"1","author":"Babu","year":"2021","journal-title":"Osteology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0645","first-page":"46","article-title":"Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2\u2013dependent regulatory dendritic cell population","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0650","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","article-title":"What is CRISPR\/Cas9?","volume":"101","author":"Redman","year":"2016","journal-title":"Arch. Dis. Childhood-Education Practice"},{"key":"10.1016\/j.intimp.2024.112724_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655122","article-title":"Fast and efficient genome editing of human FOXP3+ regulatory T cells","volume":"12","author":"Van Zeebroeck","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109494","article-title":"Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity","volume":"36","author":"Lam","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2024.112724_b0665","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611638","article-title":"Super-Treg: toward a new era of adoptive Treg therapy enabled by genetic modifications","volume":"11","author":"Amini","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b0670","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0675","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CJI.0b013e318255ada3","article-title":"Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells","volume":"35","author":"Lin","year":"2012","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0680","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cell.2011.07.033","article-title":"Control of TH17\/Treg balance by hypoxia-inducible factor 1","volume":"146","author":"Dang","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0685","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41467-022-28378-6","article-title":"In vivo CRISPR screens reveal a HIF-1\u03b1-mTOR-network regulates T follicular helper versus Th1 cells","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0690","first-page":"2547","article-title":"CRISPR\/Cas9-mediated hypoxia inducible factor-1\u03b1 knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0695","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41598-017-00508-x","article-title":"IL-1\u03b2 induced HIF-1\u03b1 inhibits the differentiation of human FOXP3+ T cells","volume":"7","author":"Feldhoff","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0700","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/ijms25010344","article-title":"Applications of Genome-Editing Technologies for Type 1 Diabetes","volume":"25","author":"El Nahas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.intimp.2024.112724_b0705","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.3390\/cells11213503","article-title":"Advanced glycation end products and inflammation in type 1 diabetes development","volume":"11","author":"Du","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.intimp.2024.112724_b0710","doi-asserted-by":"crossref","first-page":"e0236921","DOI":"10.1371\/journal.pone.0236921","article-title":"The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling","volume":"15","author":"Reed","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112724_b0715","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-020-05378-z","article-title":"Deficiency of the innate immune adaptor STING promotes autoreactive T cell expansion in NOD mice","volume":"64","author":"Akazawa","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.intimp.2024.112724_b0720","doi-asserted-by":"crossref","first-page":"p. tkad050","DOI":"10.1093\/burnst\/tkad050","article-title":"The cGAS-STING pathway: a therapeutic target in diabetes and its complications","volume":"12","author":"He","year":"2024","journal-title":"Burns Trauma"},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b0725","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.4049\/jimmunol.1800465","article-title":"A hypermorphic Nfkbid allele contributes to impaired thymic deletion of autoreactive diabetogenic CD8+ T cells in NOD mice","volume":"201","author":"Presa","year":"2018","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0730","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4049\/jimmunol.2100558","article-title":"Nfkbid overexpression in nonobese diabetic mice elicits complete type 1 diabetes resistance in part associated with enhanced thymic deletion of pathogenic CD8 T cells and increased numbers and activity of regulatory T cells","volume":"209","author":"Dwyer","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0735","article-title":"CD8+ T cells involved in metabolic inflammation in visceral adipose tissue and liver of transgenic pigs","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0740","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/db17-1467","article-title":"Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development","volume":"67","author":"Racine","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2024.112724_b0745","doi-asserted-by":"crossref","first-page":"1377322","DOI":"10.3389\/fendo.2024.1377322","article-title":"Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0750","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4049\/jimmunol.1701616","article-title":"Functional interrogation of primary human T cells via CRISPR genetic editing","volume":"201","author":"Chen","year":"2018","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0755","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b0760","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.jid.2018.09.002","article-title":"Research techniques made simple: CAR T-cell therapy","volume":"138","author":"Siddiqi","year":"2018","journal-title":"J, Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0765","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2024.112724_b0770","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","article-title":"Engineering car-t cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomarker Res."},{"key":"10.1016\/j.intimp.2024.112724_b0780","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.omtm.2021.10.010","article-title":"Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells","volume":"23","author":"Arjomandnejad","year":"2021","journal-title":"Mol. Ther.-Methods Clin. Devel."},{"issue":"557","key":"10.1016\/j.intimp.2024.112724_b0785","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26844-1","article-title":"Transient mTOR inhibition rescues 4\u20131BB CAR-Tregs from tonic signal-induced dysfunction","volume":"12","author":"Lamarth\u00e9e","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2024.112724_b0795","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1172\/JCI135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease","volume":"130","author":"Shrestha","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0800","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0805","doi-asserted-by":"crossref","first-page":"e1433518","DOI":"10.1080\/2162402X.2018.1433518","article-title":"Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma","volume":"7","author":"Quintarelli","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.112724_b0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104216","article-title":"CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice","volume":"358","author":"Fu","year":"2020","journal-title":"Cell. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0815","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/cells9061485","article-title":"Engineering strategies to enhance TCR-based adoptive T cell therapy","volume":"9","author":"Rath","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2024.112724_b0820","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2020.00257","article-title":"TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens","volume":"11","author":"Akatsuka","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0825","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/imr.13233","article-title":"Challenges and solutions for therapeutic TCR-based agents","volume":"320","author":"Malviya","year":"2023","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0830","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/intimm\/dxab052","article-title":"Engineering strategies for broad application of TCR-T-and CAR-T-cell therapies","volume":"33","author":"Watanabe","year":"2021","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b0835","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","article-title":"Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells","volume":"17","author":"Wu","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0840","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0845","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3389\/fimmu.2020.01689","article-title":"TCR redirected T cells for cancer treatment: achievements, hurdles, and goals","volume":"11","author":"Manfredi","year":"2020","journal-title":"Front. Immunol."},{"issue":"4998","key":"10.1016\/j.intimp.2024.112724_b0850","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1900952","article-title":"Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production","volume":"251","author":"Otten","year":"1991","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0855","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"7786","key":"10.1016\/j.intimp.2024.112724_b0860","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b0865","doi-asserted-by":"crossref","first-page":"e26757","DOI":"10.4161\/onci.26757","article-title":"Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody","volume":"2","author":"Choi","year":"2013","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0870","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","article-title":"Human T regulatory cells can use the perforin pathway to cause autologous target cell death","volume":"21","author":"Grossman","year":"2004","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0875","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b0880","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.4049\/jimmunol.178.8.4891","article-title":"Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4\u2212 Tregs, regulate effector T cells using FasL","volume":"178","author":"Baatar","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104224","article-title":"Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor","volume":"358","author":"Radichev","year":"2020","journal-title":"Cell. Immunol."},{"issue":"315","key":"10.1016\/j.intimp.2024.112724_b0890","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2024.112724_b0895","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.intimp.2024.112724_b0900","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs \u03b2-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"issue":"17","key":"10.1016\/j.intimp.2024.112724_b0905","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","article-title":"Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy","volume":"6","author":"Hsieh","year":"2022","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b0910","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2024.112724_b0920","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0968-0004(91)90140-Q","article-title":"Insulin hexamers: new conformations and applications","volume":"16","author":"Blader","year":"1991","journal-title":"Trends Biochem. Sci"},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0925","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00125-023-06076-2","article-title":"Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes","volume":"67","author":"Tuomela","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0930","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/imr.13254","article-title":"Eras of designer Tregs: Harnessing synthetic biology for immune suppression","volume":"320","author":"Tuomela","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112724_b0935","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.777788","article-title":"Using the T cell receptor as a biomarker in type 1 diabetes","volume":"12","author":"Nakayama","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0940","doi-asserted-by":"crossref","unstructured":"A.M. Mitchell, et al., T-cell responses to hybrid insulin peptides prior to type 1 diabetes development, Proc. Natl. Acad. Sci., 118(6): p. e2019129118, 2021.","DOI":"10.1073\/pnas.2019129118"},{"key":"10.1016\/j.intimp.2024.112724_b0945","doi-asserted-by":"crossref","first-page":"1015855","DOI":"10.3389\/fimmu.2022.1015855","article-title":"Characterizing T cell responses to enzymatically modified beta cell neo-epitopes","volume":"13","author":"Nguyen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b0950","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2024.112724_b0955","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front. Immunol."},{"issue":"665","key":"10.1016\/j.intimp.2024.112724_b0960","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b0965","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4049\/jimmunol.1700156","article-title":"Cutting edge: low-affinity TCRs support regulatory T cell function in autoimmunity","volume":"200","author":"Sprouse","year":"2018","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112724_b0970","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20040180","article-title":"CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes","volume":"199","author":"Tarbell","year":"2004","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b0975","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.20011845","article-title":"CD4+ T cells from glutamic acid decarboxylase (GAD) 65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer","volume":"196","author":"Tarbell","year":"2002","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b0980","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1084\/jem.186.10.1663","article-title":"Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice","volume":"186","author":"Verdaguer","year":"1997","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b0985","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1084\/jem.20030422","article-title":"Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells","volume":"198","author":"Yamazaki","year":"2003","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b0990","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1084\/jem.20061631","article-title":"Dendritic cell\u2013expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice","volume":"204","author":"Tarbell","year":"2007","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.112724_b0995","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.4049\/jimmunol.179.9.5845","article-title":"High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines","volume":"179","author":"Zhao","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1000","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-018-0083-6","article-title":"Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation","volume":"19","author":"Klein","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b1005","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1600-6143.2011.03650.x","article-title":"The potency of allospecific Tregs cells appears to correlate with T cell receptor functional avidity","volume":"11","author":"Tsang","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2024.112724_b1010","article-title":"Increased TCR signaling in regulatory T cells is disengaged from TCR affinity","author":"Jing","year":"2023","journal-title":"bioRxiv"},{"issue":"20","key":"10.1016\/j.intimp.2024.112724_b1015","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1073\/pnas.1715590115","article-title":"Revealing the specificity of regulatory T cells in murine autoimmune diabetes","volume":"115","author":"Spence","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112724_b1020","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomarker Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b1030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00415-021-10766-5","article-title":"Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity","volume":"269","author":"Pensato","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b1035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.24272\/j.issn.2095-8137.2021.363","article-title":"Engineered T cells and their therapeutic applications in autoimmune diseases","volume":"43","author":"Bao","year":"2022","journal-title":"Zool. Res."},{"key":"10.1016\/j.intimp.2024.112724_b1040","doi-asserted-by":"crossref","unstructured":"C. Lamarche, et al., Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion. bioRxiv, 2020.","DOI":"10.1101\/2020.06.27.175158"},{"issue":"7","key":"10.1016\/j.intimp.2024.112724_b1045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.molmed.2012.04.009","article-title":"CAR\u2013T cells and solid tumors: tuning T cells to challenge an inveterate foe","volume":"18","author":"Gilham","year":"2012","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b1050","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126194","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function","volume":"4","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b1055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/celldisc.2015.40","article-title":"Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA","volume":"1","author":"Bai","year":"2015","journal-title":"Cell Discovery"},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b1065","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.mt.6300341","article-title":"Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3","volume":"16","author":"Allan","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2024.112724_b1075","series-title":"Chimeric Antigen Receptor T Cells","first-page":"223","article-title":"Analysis of CAR-mediated tonic signaling","author":"Calderon","year":"2020"},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b1080","doi-asserted-by":"crossref","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"issue":"24","key":"10.1016\/j.intimp.2024.112724_b1085","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/cancers15245877","article-title":"Promises and pitfalls of next-generation Treg adoptive immunotherapy","volume":"15","author":"Christofi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2024.112724_b1090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.molimm.2016.01.008","article-title":"Rapamycin\/GABA combination treatment ameliorates diabetes in NOD mice","volume":"73","author":"He","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101376","article-title":"The role of rapamycin in healthspan extension via the delay of organ aging","volume":"70","author":"Zhang","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.112724_b1100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrendo.2009.276","article-title":"Stem cell and gene therapies for diabetes mellitus","volume":"6","author":"Calne","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b1105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41551-020-0602-1","article-title":"Long-term viability through selective permeability","volume":"4","author":"Coppieters","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.intimp.2024.112724_b1110","first-page":"1625","article-title":"Immunosuppression in islet transplantation","volume":"118","author":"Van Belle","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.intimp.2024.112724_b1115","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/db19-0525","article-title":"Low-dose interleukin-2 combined with rapamycin led to an expansion of CD4+ CD25+ FOXP3+ regulatory T cells and prolonged human islet allograft survival in humanized mice","volume":"69","author":"Hu","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2024.112724_b1120","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00125-012-2475-7","article-title":"Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)","volume":"55","author":"Barlow","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.intimp.2024.112724_b1125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.612737","article-title":"Tregs and mixed chimerism as approaches for tolerance induction in islet transplantation","volume":"11","author":"Pathak","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112724_b1130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b1135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5213\/inj.2014.18.2.50","article-title":"Big data analysis using modern statistical and machine learning methods in medicine","volume":"18","author":"Yoo","year":"2014","journal-title":"Int. Neurourol. J."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12967-021-02778-6","article-title":"Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era","volume":"19","author":"Akil","year":"2021","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.yamp.2019.07.010","article-title":"Machine learning in biology and medicine","volume":"2","author":"Noorbakhsh","year":"2019","journal-title":"Adv. Mol. Pathol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b1150","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3390\/biom12101444","article-title":"Exploring computational data amplification and imputation for the discovery of type 1 diabetes (T1D) biomarkers from limited human datasets","volume":"12","author":"Alcazar","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2024.112724_b1155","doi-asserted-by":"crossref","unstructured":"S. Peng, et al., Machine learning-based pathomics model to predict the infiltration of regulatory T cells and prognosis in isocitrate dehydrogenase-wild-type glioblastoma, 2023.","DOI":"10.21203\/rs.3.rs-3274237\/v1"},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b1160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trsl.2014.02.004","article-title":"Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review","volume":"164","author":"Watkins","year":"2014","journal-title":"Transl. Res."},{"key":"10.1016\/j.intimp.2024.112724_b1165","doi-asserted-by":"crossref","first-page":"1158278","DOI":"10.3389\/fimmu.2023.1158278","article-title":"The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness","volume":"14","author":"Fyvie","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b1170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.565096","article-title":"Predicting cross-reactivity and antigen specificity of T cell receptors","volume":"11","author":"Lee","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112724_b1175","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.csbj.2020.06.041","article-title":"T cell receptor sequence clustering and antigen specificity","volume":"18","author":"Vujovic","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41467-021-21879-w","article-title":"DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires","volume":"12","author":"Sidhom","year":"2021","journal-title":"Nat. Commun."},{"issue":"557","key":"10.1016\/j.intimp.2024.112724_b1185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3738","article-title":"De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection","volume":"12","author":"Beshnova","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112724_b1190","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1038\/s41467-021-25006-7","article-title":"GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"7661","key":"10.1016\/j.intimp.2024.112724_b1195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature22383","article-title":"Quantifiable predictive features define epitope-specific T cell receptor repertoires","volume":"547","author":"Dash","year":"2017","journal-title":"Nature"},{"issue":"7661","key":"10.1016\/j.intimp.2024.112724_b1200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature22976","article-title":"Identifying specificity groups in the T cell receptor repertoire","volume":"547","author":"Glanville","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2024.112724_b1205","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41587-020-0505-4","article-title":"Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening","volume":"38","author":"Huang","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"24","key":"10.1016\/j.intimp.2024.112724_b1210","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/bioinformatics\/btab446","article-title":"ClusTCR: a python interface for rapid clustering of large sets of CDR3 sequences with unknown antigen specificity","volume":"37","author":"Valkiers","year":"2021","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.intimp.2024.112724_b1215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcyt.2019.12.006","article-title":"Predicting in vitro human mesenchymal stromal cell expansion based on individual donor characteristics using machine learning","volume":"22","author":"Mehrian","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2024.112724_b1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.eswa.2021.115648","article-title":"Machine Learning analysis of the human infant gut microbiome identifies influential species in type 1 diabetes","volume":"185","author":"Fern\u00e1ndez-Edreira","year":"2021","journal-title":"Expert Syst. Appl."},{"key":"10.1016\/j.intimp.2024.112724_b1225","doi-asserted-by":"crossref","first-page":"1384984","DOI":"10.3389\/fendo.2024.1384984","article-title":"Comprehensive machine learning models for predicting therapeutic targets in type 2 diabetes utilizing molecular and biochemical features in rats","volume":"15","author":"Matboli","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112724_b1230","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/s22041665","article-title":"A machine learning approach to minimize nocturnal hypoglycemic events in type 1 diabetic patients under multiple doses of insulin","volume":"22","author":"Parcerisas","year":"2022","journal-title":"Sensors"},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b1235","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-2600(18)30300-X","article-title":"Machine learning for real-time prediction of complications in critical care: a retrospective study","volume":"6","author":"Meyer","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.112724_b1240","article-title":"Machine learning prediction of side effects for drugs in clinical trials","volume":"2","author":"Galeano","year":"2022","journal-title":"Cell Rep. Methods"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924012451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924012451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:06:33Z","timestamp":1786363593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924012451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":248,"alternative-id":["S1567576924012451"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112724","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112724"}}